Pfizer's COVID-19 vaccine faced EMA manufacturing concerns ahead of emergency nod
About a month before Pfizer and BioNTech won an emergency nod for their COVID-19 vaccine in Europe, regulators raised flags about lower-than-expected levels of intact mRNA in commercial batches, the BMJ reports.
Read more...